AK Medical Holdings (1789) Fundamentals 2026 — P/E 16.6x, Revenue Analysis | SniperIQ
AK Medical Holdings (1789) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of HK$6.2B, trading at HK$5.77 on the HKSE. This SniperIQ fundamentals page covers AK Medical Holdings's valuation (P/E 16.6x, P/B 1.9x), profitability (net margin 22.9%), revenue (¥1.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is AK Medical Holdings's market cap?
AK Medical Holdings (1789) has a market capitalization of approximately HK$6.2B, trading at HK$5.77 on the HKSE. Market cap moves with the live share price.
What is AK Medical Holdings's P/E ratio?
AK Medical Holdings's trailing twelve-month P/E ratio is 16.6x, with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is AK Medical Holdings?
AK Medical Holdings runs a net profit margin of 22.9%, a gross margin of 60.5%, and an operating margin of 25.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does AK Medical Holdings generate?
AK Medical Holdings reported revenue of ¥1.5B for fiscal year 2025, with net income of ¥339M and earnings per share (EPS) of 0.3. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does AK Medical Holdings pay a dividend?
AK Medical Holdings offers a trailing dividend yield of about 2.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is AK Medical Holdings financially healthy?
AK Medical Holdings carries a debt-to-equity ratio of 0.05x and a current ratio of 4.10x, with a market beta of -0.39. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is AK Medical Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For AK Medical Holdings (1789) the key facts are: market cap HK$6.2B, P/E 16.6x, revenue ¥1.5B, 52-week range 4.75-7.24. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track AK Medical Holdings's full fundamentals live
Get AK Medical Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.